Celularity Inc. (CELU) NASDAQ
1.17
+0(-2.57%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.17
+0(-2.57%)
Currency In USD
| Previous Close | 1.17 |
| Open | 1.19 |
| Day High | 1.2 |
| Day Low | 1.12 |
| 52-Week High | 4.35 |
| 52-Week Low | 1.01 |
| Volume | 60,402.27 |
| Average Volume | 155,265 |
| Market Cap | 28.14M |
| PE | -0.35 |
| EPS | -3.33 |
| Moving Average 50 Days | 1.27 |
| Moving Average 200 Days | 1.91 |
| Change | 0 |
Data not available
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
GlobeNewswire Inc.
Mar 10, 2026 12:30 PM GMT
Transaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational realignment reduces operating expenses
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of appr
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
GlobeNewswire Inc.
Dec 26, 2025 1:30 PM GMT
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet OzFL